Kenji Ikeda

1.2k total citations · 1 hit paper
24 papers, 1.0k citations indexed

About

Kenji Ikeda is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Kenji Ikeda has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 15 papers in Epidemiology and 3 papers in Oncology. Recurrent topics in Kenji Ikeda's work include Liver Disease Diagnosis and Treatment (13 papers), Hepatitis C virus research (13 papers) and Hepatitis B Virus Studies (9 papers). Kenji Ikeda is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Hepatitis C virus research (13 papers) and Hepatitis B Virus Studies (9 papers). Kenji Ikeda collaborates with scholars based in Japan, China and United States. Kenji Ikeda's co-authors include Kazuaki Chayama, Satoshi Saitoh, Hiromitsu Kumada, Yoko Sakai, Masamitsu Unakami, Toyomi MATSUMOTO, Akihito Tsubota, Yoshiyuki Suzuki, H. Kumada and Isao Koida and has published in prestigious journals such as Hepatology, Scientific Reports and The American Journal of Gastroenterology.

In The Last Decade

Kenji Ikeda

20 papers receiving 985 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis

1993 554 citations Kenji Ikeda Hepatology profile →

Peers

Countries citing papers authored by Kenji Ikeda

Since Specialization

Citations

This map shows the geographic impact of Kenji Ikeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Ikeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Ikeda more than expected).

Fields of papers citing papers by Kenji Ikeda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Ikeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Ikeda. The network helps show where Kenji Ikeda may publish in the future.

Co-authorship network of co-authors of Kenji Ikeda

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Ikeda. A scholar is included among the top collaborators of Kenji Ikeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Ikeda. Kenji Ikeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report 2025 ·Hepatology Research ·Yusuke Kawamura, Norio Akuta, (unknown), Masaru Matsumura, S. Okubo, Licht Tominaga, Shigeki Yamamoto, (unknown), Tetsuya Hosaka, (unknown), (unknown), (unknown), Yoshiyuki Suzuki, Kenji Ikeda, (unknown), Masaji Hashimoto, Takuyo Kozuka, Hiromitsu Kumada	0
2	Building vancomycin population pharmacokinetic model for Japanese low birth weight infants in comparing it with previously reported pediatric population pharmacokinetic models 2024 ·Journal of Infection and Chemotherapy ·(unknown), Kenji Ikeda, (unknown), Takahiro Ishikawa, Tetsuya Matsumoto	0
3	Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study 2023 ·Journal of Pain and Symptom Management ·(unknown), Kazuyuki Niki, Yoshiaki Okamoto, Tomohiro Kawamura, (unknown), Yoshinobu Matsuda, Kenji Ikeda	5
4	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system 2023 ·Scientific Reports ·(unknown), Yu‐Shi Tian, (unknown), Tatsuya Takagi, (unknown), Kenji Ikeda	14
5	A new risk estimation scale of HCC development, named JAB-HCC score (Japanese risk estimations of HBV-related HCC), shows a good discrimination capability 2015 ·Kanzo ·Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, (unknown), (unknown), Shunichiro Fujiyama, Yusuke Kawamura, (unknown), Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, (unknown), Hiromitsu Kumada	1
6	Relationship between SNPs in the IL28B region and amino acid substitutions in HCV core region in Japanese patients with chronic hepatitis C 2010 ·Kanzo ·(unknown), Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, (unknown), Hiromi Yatsuji, Tetsuya Hosaka, Masahiro Kobayashi, Yusuke Kawamura, Miharu Hirakawa, Yasuji Arase, Kenji Ikeda, Rie Mineta, Satomi Iwasaki, Sachiyo Watahiki, Yusuke Nakamura, Kazuaki Chayama, Hiromitsu Kumada	3
7	Efficacy and Safety of Combination Therapy of Natural Human Interferon .BETA. and Ribavirin in Chronic Hepatitis C Patients with Genotype 2 and High Virus Load 2010 ·Internal Medicine ·Yasuji Arase, (unknown), Norio Akuta, (unknown), Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Naoki Matsumoto, Satoshi Saito, Kenji Ikeda, (unknown), Hiromitsu Kumada	8
8	Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen 2001 ·Journal of Gastroenterology ·Fumitaka Suzuki, Kazuaki Chayama, (unknown), Norio Akuta, Takashi Someya, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, (unknown), Kenji Ikeda, Hiromitsu Kumada	15
9	Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis 2001 ·Journal of Gastroenterology ·Naoya Murashima, Kenji Ikeda, Masahiro Kobayashi, Satoshi Saitoh, Kazuaki Chayama, Akihito Tsubota, Yoshiyuki Suzuki, Fumitaka Suzuki, Yasuji Arase, Hiromitsu Kumada	9
10	Relationship between Five-Year Histological Outcome and Serial Changes in Serum Alanine Aminotransferase in Patients with Biochemical and Virological Relapse after Interferon Treatment for Chronic Hepatitis C 2000 ·Intervirology ·(unknown), Kenji Ikeda, Norio Akuta, Takashi Someya, Fumitaka Suzuki, (unknown), Yoshiyuki Suzuki, Satoshi Saitoh, (unknown), Kazuaki Chayama, (unknown)	1
11	Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course 2000 ·Journal of Gastroenterology ·Yasuji Arase, Kenji Ikeda, Kazuaki Chayama, Naoya Murashima, Akihito Tsubota, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Mariko Kobayashi, Fumitaka Suzuki, Hiromitsu Kumada	8
12	Time Course of Histological Changes in Patients With A Sustained Biochemical and Virological Response to Corticosteroid Withdrawal Therapy for Chronic Hepatitis B 1999 ·The American Journal of Gastroenterology ·Yasuji Arase, Kenji Ikeda, Naoya Murashima, Kazuaki Chayama, Akihito Tsubota, Isao Koida, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Mizuho Kobayashi, (unknown), Hiromitsu Kumada	4
13	Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection 1999 ·European Journal of Gastroenterology & Hepatology ·(unknown), Hiromitsu Kumada, Yasuji Arase, Kazuaki Chayama, (unknown), Kenji Ikeda, (unknown), (unknown), (unknown)	47
14	Pretreatment Virus Load and Multiple Amino Acid Substitutions in the Interferon Sensitivity-Determining Region Predict the Outcome of Interferon Treatment in Patients With Chronic Genotype 1B Hepatitis C Virus Infection 1997 ·Hepatology ·Kazuaki Chayama, Akihito Tsubota, Masaaki Kobayashi, K Okamoto, Masayo Hashimoto, (unknown), Hiromi Koike, Isao Koida, Y Arase, Satoshi Saitoh, Yoshiyuki Suzuki, N Murashima, Kenji Ikeda, H. Kumada	170
15	Examination in case of agreement and disagreement of HCV-genotype and HCV-serological group in chronic hepatitis C. 1994 ·Kanzo ·Mariko Kobayashi, Hiromitsu Kumada, Kenji Ikeda, Kazuaki Chayama, (unknown), (unknown), Akihito Tsubota, Isao Koida, Satomi Iwasaki, (unknown), (unknown), Michie Hashimoto	3
16	Imaging diagnosis of small hepatocellular carcinoma 1994 ·Hepatology ·Kenji Ikeda	5
17	Detection of HCV-RNA by improved nested polymerase chain reaction. 1991 ·Kanzo ·Yoko Sakai, Kazuaki Chayama, (unknown), Satoshi Saitoh, Kenji Ikeda, (unknown), Mariko Kobayashi, Hiromitsu Kumada, Tsuto MORINAGA	1
18	Sensitive and specific detection of hepatitis C virus RNA with nested polymerase chain reaction and digoxigenin labeled cDNA probe. 1991 ·Kanzo ·Kazuaki Chayama, Hiromitsu Kumada, Satoshi Saitoh, (unknown), Kenji Ikeda, Yoko Sakai, (unknown), Mariko Kobayashi, Tsuto MORINAGA	6
19	Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C 1991 ·Hepatology ·Kazuaki Chayama, Satoshi Saitoh, (unknown), Kenji Ikeda, Toyomi MATSUMOTO, Yoko Sakai, (unknown), Masamitsu Unakami, (unknown), Hiromitsu Kumada	154
20	Three cases of chronic liver disease with severe liver dysfunction after corticosteroid withdrawal therapy. 1987 ·Kanzo ·(unknown), Hiromitsu Kumada, Kenji Ikeda, Ikuo Nakamura, Minoru Okubo, Kazuaki Chayama, (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact